The science of glaucoma management: highlights of the 2020 Moorfields International Glaucoma Symposium

Held earlier this year, the 12th annual Moorfields International Glaucoma Symposium provided a forum for advanced clinical and scientific exchange in glaucoma management. The authors describe the key presentation themes and debates, highlighting specific topics of interest to glaucoma specialists....

Thinking outside the box – adapting to the COVID-19 lockdown

How can we avoid further delays to follow-up in glaucoma patients? The author asks if there is a socially distanced way to check IOPs in those at high risk of losing vision. Glaucoma is an asymptomatic condition. Loss of the...

Forward-tilt technique for intraocular pressure measurement in upgaze

The authors suggest a technique to improve the accuracy of measuring IOP in upgaze using Goldmann applanation tonometry. Graves’ ophthalmopathy, also known as thyroid eye disease, is an autoimmune inflammatory condition affecting the orbit and periorbital tissues [1]. It was...

Educational concerns and anxiety levels amongst ophthalmology trainees during the COVID-19 pandemic

How concerned are ophthalmology trainees about the present impact and the future consequences of suspended ophthalmic training programmes? Researchers in the West of Scotland investigate. Anxiety, stress and the longer-term stress reaction of burnout often go unrecognised, yet are known...

The Re-humanising Revolution: Breaking the conspiracy of silence

Over the last few years, the mental and emotional wellbeing of those who work in medicine has come under scrutiny. The author introduces a new resource. Working in healthcare has always been stressful but never more so than today. In...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Coming to terms with AI

A machine might be called intelligent if its response to questions could convince a person that it was human, a test proposed by Alan Turing in 1950 [1]. The author considers potential applications of artificial intelligence (AI) using machine learning...

Sharing best practice and landmark evidence in glaucoma care

Evolving technology, best practice and landmark evidence in glaucoma care were reviewed by an international expert faculty in session presentations and debates during the 11th Moorfields International Glaucoma Symposium 2019. The authors were meeting chairs and provide an overview of...

Quality matters in the management of serious eye disorders

The author discusses the first quality standard for serious eye disorders from NICE and takes a look at new care models for enhanced service delivery. Patient backlogs pose risks to patient safety, with research showing that people are losing sight...

The ‘theatre of the mind’: Charles Bonnet Syndrome and Esme’s Umbrella

The founder of Esme’s Umbrella shares her experience with the poorly understood condition Charles Bonnet Syndrome and the creation of the campaign. Many years ago, when I was a young actress, I was in an American play called ‘Butterflies are...

Childhood glaucoma

When a child is given a diagnosis of glaucoma, the impact upon that child and their family is enormous; equivalent to the diagnosis of a cancer [14]. This article outlines the knowledge, techniques and approaches that offer solutions to the...

Eye disease patients have more opportunity than ever to take part in NHS research studies

A new report highlights how 76% of UK hospitals now offer patients the opportunity to take part in studies of eye disease to improve research and innovation. ‘Ophthalmology research in the UK’s National Health Service: the structure and performance of...